CD123 Interaction class drugs
1 result
Elzonris (tagraxofusp)
(tagraxofusp)Stemline Therapeutics, Inc.
Usage: ELZONRIS is indicated for treating blastic plasmacytoid dendritic cell neoplasm (BPDCN) in adults and pediatric patients aged 2 years and older.